Akt Inhibitor MK2206

Phase 2Small molecule

NNational Cancer Institute (NCI)

Akt Inhibitor MK2206 is one of 462 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

461

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Liver CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Esophageal CancerPhase 1

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Liver CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

MelanomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Akt Inhibitor MK2206

NNational Cancer Institute (NCI)

Phase 2

7 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 5

Acupan

YYonsei University

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Avastin

Roche

Preclinical

4 8

Paracetamol

GSK

Preclinical

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer7 trials

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01281163·4 enrolled

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01263145·34 enrolled

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01277757·30 enrolled

Show 4 more trials

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01776008·16 enrolled

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01245205·28 enrolled

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01319539·12 enrolled

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01344031·31 enrolled

Acute Myeloid Leukemia2 trials

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01907815·24 enrolled

AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01253447·19 enrolled

Kidney Cancer2 trials

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01239342·43 enrolled

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01480154·62 enrolled

Pancreatic Cancer2 trials

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01658943·137 enrolled

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01783171·42 enrolled

Non-Small Cell Lung Cancer1 trial

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01294306·80 enrolled

18 more indications

Platinum-resistant1 trial

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01283035·6 enrolled

Melanoma1 trial

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01519427·2 enrolled

Chronic Lymphocytic Leukemia1 trial

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01369849·15 enrolled

Metastatic1 trial

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01604772·16 enrolled

Liver Cancer1 trial

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01239355·15 enrolled

Triple-Negative Breast Cancer1 trial

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01964924·37 enrolled

Leukemia1 trial

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01231919·45 enrolled

Esophageal Cancer1 trial

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01705340·60 enrolled

Endometrial Cancer1 trial

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01307631·37 enrolled

Locally Advanced1 trial

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01802320·18 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01481129·22 enrolled

Metastatic Head and Neck Cancer1 trial

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01349933·21 enrolled

Bile Duct Cancer1 trial

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01859182

Biliary Cancer1 trial

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01425879·8 enrolled

Gastroesophageal Junction Cancer1 trial

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01260701·75 enrolled

Lymphoma1 trial

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01258998·60 enrolled

Recurrent Prostate Carcinoma1 trial

Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01251861·108 enrolled

Unspecified1 trial

Studying Different Formulations of SR13668 in Healthy Volunteers

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00896207·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Akt Inhibitor MK2206. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Akt Inhibitor MK2206 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Akt Inhibitor MK2206. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Akt Inhibitor MK2206

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer7 trials

Acute Myeloid Leukemia2 trials

Kidney Cancer2 trials

Pancreatic Cancer2 trials

Non-Small Cell Lung Cancer1 trial

Platinum-resistant1 trial

Melanoma1 trial

Chronic Lymphocytic Leukemia1 trial

Metastatic1 trial

Liver Cancer1 trial

Triple-Negative Breast Cancer1 trial

Leukemia1 trial

Esophageal Cancer1 trial

Endometrial Cancer1 trial

Locally Advanced1 trial

Diffuse Large B-Cell Lymphoma1 trial

Metastatic Head and Neck Cancer1 trial

Bile Duct Cancer1 trial

Biliary Cancer1 trial

Gastroesophageal Junction Cancer1 trial

Lymphoma1 trial

Recurrent Prostate Carcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News